Cargando…

Genomic variations within matrix metalloproteinase-9 and severe sepsis

Detalles Bibliográficos
Autores principales:	Chen, Q, Jin, Y, Fang, X
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084240/ http://dx.doi.org/10.1186/cc7518

Ejemplares similares

Contribution of genomic variations within human β-defensin 1 to incidence and outcome of severe sepsis
por: Fang, X, et al.
Publicado: (2007)

Impact of pro-domain stability of matrix metalloproteinase-8 on the outcome of sepsis
por: McLaughlin, J, et al.
Publicado: (2011)

Severe sepsis: international and specialty variations in initial management
por: Reade, MC, et al.
Publicado: (2008)

Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2009)

Matrix metalloproteinases and their inhibitors as biomarkers of severity in sepsis
por: Lorente, Leonardo, et al.
Publicado: (2010)

Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours
por: Pennington, CJ, et al.
Publicado: (2008)

Endothelin-1 induces extracellular matrix degradation via matrix metalloproteinases induction in human osteosarcoma cells
por: Felx, M, et al.
Publicado: (2004)

Influence of TIMP-1/MMP-9 ratio on the severity and mortality in sepsis
por: Lorente, L, et al.
Publicado: (2010)

Influence of TIMP-1/MMP-9 ratio on the severity and mortality in sepsis
por: Lorente, L, et al.
Publicado: (2011)

Matrix Metalloproteinase-9 and Tissue Inhibitor of Matrix Metalloproteinase-1 in Sepsis after Major Abdominal Surgery
por: Bojic, Suzana, et al.
Publicado: (2018)

Serum imbalance between the extracellular matrix metalloproteinases (MMP-2 and MMP-9) and their tissue inhibitor (TIMP-1) in patients with food and airborne allergy
por: Kuźmiński, A, et al.
Publicado: (2013)

Genetic variation of TNF is associated with sepsis syndrome and death in severely injured patients
por: Little, S, et al.
Publicado: (2006)

Neu1 sialidase and matrix metalloproteinase-9 cross-talk in alliance with insulin receptors is an essential molecular signaling platform for insulin-induced receptor activation
por: Alghamdi, Farah G, et al.
Publicado: (2014)

Alterations of caspase 9 mRNA gene expression in survivors and nonsurvivors of severe sepsis
por: White, M, et al.
Publicado: (2010)

Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis
por: Gäddnäs, Fiia P, et al.
Publicado: (2010)

Microparticles from inflammatory cells are strong inducers of matrix metalloproteinases and inflammatory cytokines in synovial fibroblasts
por: Distler, JHW, et al.
Publicado: (2005)

Levosimendan in myocardial depression due to severe sepsis
por: Malik, M, et al.
Publicado: (2007)

Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?
por: Hoffmann, Ursula, et al.
Publicado: (2009)

Oxygen radical production determines chondrocyte death and regulates matrix metalloproteinase-mediated matrix degradation during interferon gamma-accelerated immune complex arthritis
por: van Lent, PLEM, et al.
Publicado: (2005)

Impact of the Surviving Sepsis Campaign implementation on severe sepsis outcome
por: Silva, E
Publicado: (2011)

Costs of severe sepsis according to the guidelines of the 'Surviving Sepsis Campaign'
por: de Anda, G Vazquez, et al.
Publicado: (2005)

Epidemiology of severe sepsis in India
por: Chatterjee, S, et al.
Publicado: (2009)

Epidemiology of severe sepsis in India
por: Todi, S, et al.
Publicado: (2007)

The association between blood glucose levels and matrix-metalloproteinase-9 in early severe sepsis and septic shock
por: Sachwani, Gul R., et al.
Publicado: (2016)

Prognostic factors of severe sepsis: a result of Korean sepsis registry system
por: Chun, Byung-Chul, et al.
Publicado: (2008)

AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction
por: Yamaoka, Kunihiro, et al.
Publicado: (2012)

Laminin type 1 augments the transforming growth factor beta-induced expression of matrix metalloproteinase 3 in synovial fibroblasts
por: Hoberg, M, et al.
Publicado: (2005)

Epidemiology of severe sepsis in India: an update
por: Todi, S, et al.
Publicado: (2010)

Obesity and inflammatory markers in severe sepsis
por: Simon, P, et al.
Publicado: (2013)

Tissue oxygenation in patients with severe sepsis
por: Oei, A, et al.
Publicado: (2014)

Systemic symptoms as markers for severity in sepsis
por: Edman-Wallér, J, et al.
Publicado: (2015)

Clinical study on the relationship of adrenal function and prognosis in patients with severe sepsis
por: Yang, Y
Publicado: (2006)

Pro-atrial natriuretic peptide in patients with sepsis, severe sepsis and septic shock
por: Prucha, M, et al.
Publicado: (2005)

Serum pro-metalloproteinase 9 is a predictor of length of ICU and hospital stay in patients with septic shock
por: Costa, NA, et al.
Publicado: (2013)

Impact of synthetic colloids on organ function in patients with severe sepsis
por: Bayer, O, et al.
Publicado: (2011)

Antibiotic-related acute effects within the intestinal microcirculation in experimental sepsis
por: Lehmann, CH, et al.
Publicado: (2008)

Low dose immunoglobulin g for treatment of severe sepsis and septic shock
por: Iizuka, Y, et al.
Publicado: (2015)

Epidemiology and outcome of patients with severe sepsis in six Spanish ICUs
por: Lorente, L, et al.
Publicado: (2009)

Different hemoglobin thresholds for transfusion in patients with severe sepsis and septic shock
por: Kamio, T, et al.
Publicado: (2015)

A retrospective investigation of the pmx-dhp's efficacy in 88 severe sepsis cases
por: Tanaka, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v64pedeg7863da1mip7mv409f2